As an integral part of N8 Biosciences, a holding company committed to the extensive application of Ceragenins, N8 Biosciences is making strides in two key areas :
- The development of CeraShield, a specialized coating for medical devices, aimed at preventing infections.
- Through our subsidiary, Kinnear Pharmaceuticals (www.kinnearpharma.com), we’re advancing therapeutic research and drug development. Our focus is on creating treatments for a range of conditions, including cystic fibrosis (CF) and Kostmann’s disease, leveraging the unique properties of Ceragenins that mimic the activity of naturally occurring innate immune system compounds such as LL-37.
The Company’s proprietary technology is based on Dr. Paul B. Savage’s research and invention at Brigham Young University (BYU).
What sets our Ceragenins apart? These synthetic molecules are designed to mimic endogenous host defense peptides – nature’s own way of combating pathogens. They replicate the multifaceted activities of natural antimicrobial peptides, but with enhanced stability and manufacturability. Unlike peptides, Ceragenins resist proteolytic degradation and can be produced on a large scale, making them a practical solution for widespread use.